Skip to main content
Fig. 2 | Lipids in Health and Disease

Fig. 2

From: Saturated and mono-unsaturated lysophosphatidylcholine metabolism in tumour cells: a potential therapeutic target for preventing metastases

Fig. 2

Metabolism of saturated and unsaturated LysoPC and FFA species by solid tumour cell. a: Time course removal of exogenously added saturated and unsaturated LysoPC species (18:0 and 18:1) in cell culture supernatants of solid tumour cell lines B16.F10, MV3, and AsPC1 cells. b: Changes of cellular lipid FA ratios of FA C18:0 and FA C18:1 (in % of total FA) in LysoPC (C18:0 and C18:1) treated cells. c: FA composition in B16.F10 cells after treatment with two LysoPC species simultaneously in different ratios (for 48 h). d: Release of FFA to cell culture supernatants, analysed by an enzymatic FFA assay. B16.F10 mouse melanoma cells were incubated with LysoPC 17:0, C18:1, and BSA medium. Media without contact to cells were analysed as control. e: Comparison of incorporation of different LysoPC species and the corresponding FFA into B16.F10 mouse melanoma cells. Increases of the respective FA are shown in time course experiments. f: Comparison of LysoPC degradation in B16.F10 tumour cells (green) with the degradation in supernatant after removal of the tumour cells (blue), and LysoPC containing medium without cell contact (red). B16.F10 cells were cultivated in LysoPC 17:0 medium. After 6 h, supernatant was separated from the cells and further incubated (blue)

Back to article page